Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a pow... Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company's drug candidates within a tumor. Inspyr's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 402 | 0.0001 | CS |
4 | 0 | 0 | 0.0001 | 0.0002 | 1.0E-6 | 31860 | 2.173E-5 | CS |
12 | 9.9E-5 | 9900 | 1.0E-6 | 0.0002 | 1.0E-6 | 55230 | 7.699E-5 | CS |
26 | 0 | 0 | 0.0001 | 0.0002 | 1.0E-6 | 35731 | 7.609E-5 | CS |
52 | -0.0025 | -96.1538461538 | 0.0026 | 0.01 | 1.0E-6 | 134148 | 0.00070907 | CS |
156 | -0.0267 | -99.6268656716 | 0.0268 | 0.0278 | 1.0E-6 | 175359 | 0.01279036 | CS |
260 | -0.0998 | -99.8998998999 | 0.0999 | 0.12 | 1.0E-6 | 259825 | 0.02247702 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約